ArticleFuture medicinal chemistry2011
Target repurposing for neglected diseases.
Article in Future medicinal chemistry, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed.
- Potent kinase inhibitors from the Merck KGaA OGHL: Novel hits against Trypanosoma brucei with potential for repurposing.PLoS neglected tropical diseases · 2025Article
- A Machine Learning Algorithm Suggests Repurposing Opportunities for Targeting Selected GPCRs.International journal of molecular sciences · 2024Article
- Computer-aided pattern scoring - A multitarget dataset-driven workflow to predict ligands of orphan targets.Scientific data · 2024Article
- Integrated Computational Approaches for Drug Design Targeting Cruzipain.International journal of molecular sciences · 2024Article
- Medicinal polypharmacology-a scientific glossary of terminology and concepts.Frontiers in pharmacology · 2024Review
- Tyrosine Kinase Inhibitors Display Potent Activity against Cryptosporidium parvum.Microbiology spectrum · 2023Article
- Computational approaches for drug discovery against trypanosomatid-caused diseases.Parasitology · 2020Review
- In Vitro and in Vivo Activity of mTOR Kinase and PI3K Inhibitors AgainstMolecules (Basel, Switzerland) · 2020Article
- Chalcones as a basis for computer-aided drug design: innovative approaches to tackle malaria.Future medicinal chemistry · 2019Article
- Drug repurposing for new, efficient, broad spectrum antivirals.Virus research · 2019Review
- Identification andFrontiers in immunology · 2019Article
- Series of Alkynyl-Substituted Thienopyrimidines as Inhibitors of Protozoan Parasite Proliferation.ACS medicinal chemistry letters · 2018Article
- An automated high-throughput system for phenotypic screening of chemical libraries on C. elegans and parasitic nematodes.International journal for parasitology. Drugs and drug resistance · 2018Article
- 3D-e-Chem: Structural Cheminformatics Workflows for Computer-Aided Drug Discovery.ChemMedChem · 2018Article
- Article
- Selective inhibition of RNA polymerase I transcription as a potential approach to treat African trypanosomiasis.PLoS neglected tropical diseases · 2017Article
- Discovery of a Carbazole-Derived Lead Drug for Human African Trypanosomiasis.Scientific reports · 2016Article
- Repurposing strategies for tropical disease drug discovery.Bioorganic & medicinal chemistry letters · 2016Review
- Identification of "Preferred" Human Kinase Inhibitors for Sleeping Sickness Lead Discovery. Are Some Kinases Better than Others for Inhibitor Repurposing?ACS infectious diseases · 2016Article
- A Multilayer Network Approach for Guiding Drug Repositioning in Neglected Diseases.PLoS neglected tropical diseases · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Infectious diseases are an enormous burden to global health and ,since drug discovery is costly, those infectious diseases that affect the developing world are often not pursued by commercial drug-discovery efforts. Therefore, pragmatic means by which new therapeutics can be discovered are needed. One such approach is target repurposing, where pathogen targets are matched with homologous human targets that have been pursued for drug discovery for other indications. In many cases, the medicinal chemistry, structural biology and biochemistry knowledge around these human targets can be directly repurposed to launch and accelerate new drug-discovery efforts against the pathogen targets. This article describes the overarching strategy of target repurposing as a tool for initiating and prosecuting neglected disease drug-discovery programs, highlighting this approach with three case studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.